Current and emerging therapies for the management of functional gastrointestinal disorders

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 2, 2011, Pages 87-99

  Craig, Orla F ^a   Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

antibiotics; antidepressants; cognitive behavioural therapy; functional dyspepsia; functional gastrointestinal disorders; functional heartburn; irritable bowel syndrome; probiotics; serotonin

Indexed keywords

ALGINIC ACID; ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BACLOFEN; CITALOPRAM; DEXLOXIGLUMIDE; ESCITALOPRAM; GHRELIN; IMIPRAMINE; ISPAGULA; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; MEBEVERINE; PAROXETINE; PEPPERMINT OIL; PLACEBO; PROBIOTIC AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; BACTERIAL GROWTH; BLOATING; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; DEFECATION URGENCY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FOOD INTAKE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HEARTBURN; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNE RESPONSE; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LOW DRUG DOSE; NAUSEA; PAIN; PATHOGENESIS; POSTPRANDIAL PAIN; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SMOOTH MUSCLE SPASM; SOMNOLENCE; TRAVELLER DIARRHEA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79960055925     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622310389507     Document Type: Review

References (110)

1. Akamizu T. Iwakura H. Ariyasu H. Hosoda H. Murayama T. Yokode M. et al (2008) Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol 158: 491–498.
2. Akehurst R.L. Brazier J.E. Mathers N. O'Keefe C. Kaltenthaler E. Morgan A. et al (2002) Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmaco Economics 20: 455–462.
3. Ambizas E.M. Ginzburg R. (2007) Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother 41: 957–964.
4. Andresen V. Camilleri M. Busciglio I.A. Grudell A. Burton D. McKinzie S. et al (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761–768.
5. Arffmann S. Andersen J.R. Hegnhoj J. Schaffalitzky de Muckadell O.B. Mogensen N.B. Krag E. (1985) The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. Scand J Gastroenterol 20: 295–298.
6. Atkinson W. Sheldon T.A. Shaath N. Whorwell P.J. (2004) Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 53: 1459–1464.
7. Aziz Q. Thompson D.G. Ng V.W. Hamdy S. Sarkar S. Brammer M.J. et al (2000) Cortical processing of human somatic and visceral sensation. J Neurosci 20: 2657–2663.
8. Barbara G. Stanghellini V. Cremon C. de Giorgio R. Fronzoni L. Serra M. et al (2009) Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 27(Suppl. 1): 115–121.
9. Barbera R. Feinle C. Read N.W. (1995) Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 7: 1051–1057.
10. Brandt L.J. Chey W.D. Foxx-Orenstein A.E. Schiller L.R. Schoenfeld P.S. Spiegel B.M. et al (2009) An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104(Suppl. 1): S1–S35.
11. Brenner D.M. Moeller M.J. Chey W.D. Schoenfeld P.S. (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 1033–1049; quiz 1050.
12. Camilleri M. (2010) Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther 31: 35–46.
13. Chial H.J. Camilleri M. Burton D. Thomforde G. Olden K.W. Stephens D. (2003) Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 284: G130–G137.
14. Cipriani A. Brambilla P. Furukawa T. Geddes J. Gregis M. Hotopf M. et al (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 4; CD004185.
15. Cipriani A. Furukawa T.A. Salanti G. Geddes J.R. Higgins J.P. Churchill R. et al (2009 a) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373: 746–758.
16. Cipriani A. Santilli C. Furukawa T.A. Signoretti A. Nakagawa A. McGuire H. et al (2009 b) Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2; CD006532.
17. Codling C. O'Mahony L. Shanahan F. Quigley E.M. Marchesi J.R. (2010) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55: 392–397.
18. Dainese R. Galliani E.A. de Lazzari F. Di Leo V. Naccarato R. (1999) Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol 94: 1892–1897.
19. Dean B.B. Gano A.D. Jr Knight K. Ofman J.J. Fass R. (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2: 656–664.
20. Dinan T.G. Clarke G. Quigley E.M. Scott L.V. Shanahan F. Cryan J. et al (2008) Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 103: 2570–2576.
21. Dolin B.J. (2009) Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 31: 655–659.
22. Drossman D.A. (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130: 1377–1390.
23. Drossman D.A. Chey W.D. Johanson J.F. Fass R. Scott C. Panas R. et al (2009) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29: 329–341.
24. Drossman D.A. Creed F.H. Olden K.W. Svedlund J. Toner B.B. Whitehead W.E. (1999) Psychosocial aspects of the functional gastrointestinal disorders. Gut 45(Suppl. 2): II25– II30.
25. Drossman D.A. Li Z. Andruzzi E. Temple R.D. Talley N.J. Thompson W.G. et al (1993) US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38: 1569–1580.
26. Fass R. Sifrim D. (2009) Management of heartburn not responding to proton pump inhibitors. Gut 58: 295–309.
27. Feinle C. Meier O. Otto B. D'Amato M. Fried M. (2001) Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 48: 347–355.
28. Ford A.C. Brandt L.J. Young C. Chey W.D. Foxx-Orenstein A.E. Moayyedi P. (2009 a) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 104: 1831–1843; quiz 1844.
29. Ford A.C. Spiegel B.M. Talley N.J. Moayyedi P. (2009 b) Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 7: 1279–1286.
30. Ford A.C. Talley N.J. Schoenfeld P.S. Quigley E.M. Moayyedi P. (2009 c) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58: 367–378.
31. Ford A.C. Talley N.J. Spiegel B.M. Foxx-Orenstein A.E. Schiller L. Quigley E.M. et al (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337; a2313.
32. Gershon M.D. Tack J. (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397–414.
33. Gorard D.A. Libby G.W. Farthing M.J. (1994) Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8: 159–166.
34. Grigoleit H.G. Grigoleit P. (2005) Peppermint oil in irritable bowel syndrome. Phytomedicine 12: 601–606.
35. Gwee K.A. Collins S.M. Read N.W. Rajnakova A. Deng Y. Graham J.C. et al (2003) Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 52: 523–526.
36. Hills J.M. Aaronson P.I. (1991) The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 101: 55–65.
37. Hiyama T. Yoshihara M. Matsuo K. Kusunoki H. Kamada T. Ito M. et al (2007) Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 22: 304–310.
38. Hojo M. Miwa H. Yokoyama T. Ohkusa T. Nagahara A. Kawabe M. et al (2005) Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 40: 1036–1042.
39. Johanson J.F. Drossman D.A. Panas R. Wahle A. Ueno R. (2008 a) Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27: 685–696.
40. Johanson J.F. Morton D. Geenen J. Ueno R. (2008 b) Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103: 170–177.
41. Karamanolis G. Vanuytsel T. Sifrim D. Bisschops R. Arts J. Caenepeel P. et al (2008) Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 53: 2387–2393.
42. Khoshoo V. Armstead C. Landry L. (2006) Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 23: 191–196.
43. Kim D.Y. Camilleri M. (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2698–2709.
44. Knill-Jones R.P. (1991) Geographical differences in the prevalence of dyspepsia. Scand J Gastroenterol Suppl 182: 17–24.
45. Koek G.H. Sifrim D. Lerut T. Janssens J. Tack J. (2003) Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52: 1397–1402.
46. Koloski N.A. Talley N.J. Boyce P.M. (2000) The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 95: 67–71.
47. Lee K.J. Cha D.Y. Cheon S.J. Yeo M. Cho S.W. (2009) Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion 80: 58–63.
48. Lehmann A. Jensen J.M. Boeckxstaens G.E. (2010) GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol 58: 287–313.
49. Liebregts T. Adam B. Bredack C. Roth A. Heinzel S. Lester S. et al (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132: 913–920.
50. Lieverse R.J. Jansen J.B. Lamers C.B. (1993) Cholecystokinin and satiation. Neth J Med 42: 146–152.
51. Locke G.R. III Lin S.C. Talley N.J. (2005) Psychiatric disease and functional GI disorders in the community: more evidence for a casual link? Am J Gastroenterol 100: 248–249.
52. Longstreth G.F. Drossman D.A. (2005) Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 3: 397–400.
53. Longstreth G.F. Wilson A. Knight K. Wong J. Chiou C.F. Barghout V. et al (2003) Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am J Gastroenterol 98: 600–607.
54. Malinen E. Rinttila T. Kajander K. Matto J. Kassinen A. Krogius L. et al (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100: 373–382.
55. Matsueda K. Harasawa S. Hongo M. Hiwatashi N. Sasaki D. (2008 a) A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 77: 225–235.
56. Matsueda K. Harasawa S. Hongo M. Hiwatashi N. Sasaki D. (2008 b) A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43: 1202–1211.
57. Maxion-Bergemann S. Thielecke F. Abel F. Bergemann R. (2006) Costs of irritable bowel syndrome in the UK and US. Pharmaco Economics 24: 21–37.
58. McKee D.P. Quigley E.M. (1993) Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 38: 1773–1782.
59. McQuay H.J. Tramer M. Nye B.A. Carroll D. Wiffen P.J. Moore R.A. (1996) A systematic review of antidepressants in neuropathic pain. Pain 68: 217–227.
60. Moayyedi P. Ford A.C. Talley N.J. Cremonini F. Foxx-Orenstein A.E. Brandt L.J. et al (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325–332.
61. Moayyedi P. Soo S. Deeks J. Delaney B. Innes M. Forman D. (2006) Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 4; CD001960.
62. Modlin I.M. Hunt R.H. Malfertheiner P. Moayyedi P. Quigley E.M. Tytgat G.N. et al (2009) Diagnosis and management of non-erosive reflux disease–the Vevey NERD Consensus Group. Digestion 80: 74–88.
63. Moran T.H. Dailey M.J. (2009) Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology 150: 2526–2530.
64. Morcos A. Dinan T. Quigley E.M. (2009) Irritable bowel syndrome: role of food in pathogenesis and management. J Dig Dis 10: 237–246.
65. Murray C.D. Martin N.M. Patterson M. Taylor S.A. Ghatei M.A. Kamm M.A. et al (2005) Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 54: 1693–1698.
66. Nayak A.K. Karnad D.R. Abraham P. Mistry F.P. (1997) Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called ‘chronic amebiasis’. Indian J Gastroenterol 16: 137–139.
67. Nobaek S. Johansson M.L. Molin G. Ahrne S. Jeppsson B. (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95: 1231–1238.
68. Nojkov B. Rubenstein J.H. Adlis S.A. Shaw M.J. Saad R. Rai J. et al (2008) The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 27: 473–482.
69. O'Mahony L. McCarthy J. Kelly P. Hurley G. Luo F. Chen K. et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541–551.
70. Ohman L. Isaksson S. Lindmark A.C. Posserud I. Stotzer P.O. Strid H. et al (2009) T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 104: 1205–1212.
71. Pae C.U. Masand P.S. Ajwani N. Lee C. Patkar A.A. (2007) Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 61: 1708–1718.
72. Park M.I. Camilleri M. (2006) Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil 18: 595–607.
73. Pilichiewicz A.N. Feltrin K.L. Horowitz M. Holtmann G. Wishart J.M. Jones K.L. et al (2008) Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol 103: 2613–2623.
74. Pimentel M. (2009) Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 18: 349–358.
75. Pimentel M. Chatterjee S. Chow E.J. Park S. Kong Y. (2006 a) Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 51: 1297–1301.
76. Pimentel M. Kong Y. Park S. (2003) Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol 98: 2700–2704.
77. Pimentel M. Park S. Mirocha J. Kane S.V. Kong Y. (2006 b) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557–563.
78. Quigley E.M. (2007) Probiotics in irritable bowel syndrome: an immunomodulatory strategy? J Am Coll Nutr 26: 684S–690S.
79. Quigley E.M. (2009) Prebiotics for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 3: 487–492.
80. Quigley E.M. Bytzer P. Jones R. Mearin F. (2006) Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 38: 717–723.
81. Ragnarsson G. Bodemar G. (1998) Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 10: 415–421.
82. Ronkainen J. Aro P. Storskrubb T. Johansson S.E. Lind T. Bolling-Sternevald E. et al (2005) High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 40: 275–285.
83. Saito Y.A. Schoenfeld P. Locke G.R. III (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97: 1910–1915.
84. Sarnelli G. Janssens J. Tack J. (2001) Effect of intranasal sumatriptan on gastric tone and sensitivity to distension. Dig Dis Sci 46: 1591–1595.
85. Savarino E. Pohl D. Zentilin P. Dulbecco P. Sammito G. Sconfienza L. et al (2009) Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58: 1185–1191.
86. Sharara A.I. Aoun E. Abdul-Baki H. Mounzer R. Sidani S. Elhajj I. (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326–333.
87. Shekhar C. Whorwell P.J. (2009) Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs 14: 673–685.
88. Sifrim D. (2004) Acid, weakly acidic and non-acid gastro-oesophageal reflux: differences, prevalence and clinical relevance. Eur J Gastroenterol Hepatol 16: 823–830.
89. Silk D.B. Davis A. Vulevic J. Tzortzis G. Gibson G.R. (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29: 508–518.
90. Simren M. Mansson A. Langkilde A.M. Svedlund J. Abrahamsson H. Bengtsson U. et al (2001) Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 63: 108–115.
91. Snook J. Shepherd H.A. (1994) Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 8: 511–514.
92. Soo S. Moayyedi P. Deeks J. Delaney B. Lewis M. Forman D. (2005) Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2; CD002301.
93. Tack J. Bisschops R. Sarnelli G. (2004) Pathophysiology and treatment of functional dyspepsia. Gastroenterology 1274: 1239–1255.
94. Tack J. Coulie B. Wilmer A. Andrioli A. Janssens J. (2000) Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 46: 468–473.
95. Tack J. Depoortere I. Bisschops R. Verbeke K. Janssens J. Peeters T. (2005) Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 22: 847–853.
96. Tack J. Piessevaux H. Coulie B. Caenepeel P. Janssens J. (1998) Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115: 1346–1352.
97. Tack J. van Den Elzen B. Tytgat G. Wajs E. van Nueten L. de Ridder F. et al (2009) A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 21: 619–626; e623–e614.
98. Takahashi M. Iwamoto K. Kawamura Y. Nakamura Y. Ishihara R. Uchiyama Y. et al (2010) The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol 25: 260–267.
99. Talley N.J. Choung R.S. (2009) Whither dyspepsia? A historical perspective of functional dyspepsia, and concepts of pathogenesis and therapy in 2009. J Gastroenterol Hepatol 24(Suppl. 3): S20–S28.
100. Talley N.J. Vakil N. (2005) Guidelines for the management of dyspepsia. Am J Gastroenterol 100: 2324–2337.
101. Thompson W.G. Irvine E.J. Pare P. Ferrazzi S. Rance L. (2002) Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 47: 225–235.
102. Tonini M. Pace F. (2006) Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 24: 59–69.
103. Trimble K.C. Farouk R. Pryde A. Douglas S. Heading R.C. (1995) Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 40 (8): 1607–1613.
104. Tsoukali E. Sifrim D. (2010) The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled? J Neurogastroenterol Motil 16 (3): 258–264.
105. Ueno H. Shiiya T. Nakazato M. (2010) Translational research of ghrelin. Ann N Y Acad Sci 1200: 120–127.
106. Vakil N. Laine L. Talley N.J. Zakko S.F. Tack J. Chey W.D. et al (2008) Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 103: 1906–1919.
107. Wang A. Liao X. Xiong L. Peng S. Xiao Y. Liu S. et al (2008) The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 8: 43–44.
108. Yang J. Lee H.R. Low K. Chatterjee S. Pimentel M. (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 53: 169–174.
109. Zijdenbos I.L. de Wit N.J. van der Heijden G.J. Rubin G. Quartero A.O. (2009) Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 1; CD006442.
110. Zwetchkenbaum J. Burakoff R. (1988) The irritable bowel syndrome and food hypersensitivity. Ann Allergy 61: 47–49.